Robert Orlowski, Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared on X:
“Myeloma Paper of the Day:
Phase 3 of felzartamab (anti-CD38 w/ potent ADCC & ADCP but attenuated CDC) + len/dex vs len/dex for RRMM shows median PFS 18.9 vs 10.4 mos (HR 0.62, CI 0.45-0.86); common grade 3-4 AEs cytopenias, pneumonia, hypoK, URI.”
Title: Felzartamab plus lenalidomide–dexamethasone versus lenalidomide–dexamethasone for relapsed or refractory multiple myeloma: an open-label, parallel-controlled, randomised, phase 3 trial
Authors: Haiyan He, Jingjing Shang, Yafei Wang, Zhongjun Xia, Fangbing Zhu, Yanli Yang, Baijun Fang, Wenming Chen, Bing Chen, Zhen Cai, Hui Zhou, Yajun Li, Hong Liu, Lijuan Chen, Yan Liu, Zhongxia Huang, Pengyun Zeng, Jie Jin, Yan Li, Jianqing Mi, Zeping Zhou, Sujun Gao, Yaming Xi, Qingming Wang, Chunkang Chang, Xin Du, Shang-Yi Huang, Hao-Yuan Wang, Po-Shen Ko, Zonghong Shao, Jun Luo, Shunqing Wang, Jinwen Huang, Mingshen Dai, Tonghua Yang, Rong Zhan, Bin Liang, Ming-Chung Wang, Suijing Wu, Liye Zhong, Yongqiang Wei, Hongxiang Wang, Huijing Wu, Juan Li, Chieh-Lin Teng, Yuan Meng, Minfang Wu, Ping Yang, Xi Chen, Andrew X Zhu, Weijun Fu, Depei Wu, Chengcheng Fu
You can read the full article on The Lancet Haematology.
You can find other articles featuring Robert Orlowski on OncoDaily.
